Abstract 330P
Background
After radiotherapy (RT) to the left breast, the long-term risk of developing various cardiovascular diseases may increase. In our study, we present how deep inspiration treatment changes the doses of organs at risk (OAR), especially the heart. Furthermore, we examined if there is a relationship between the size of the irradiated target area and the dose on the heart.
Methods
From May 2016 to August 2020, 503 patients with left-sided breast cancer underwent RT at our institute. Since May 2018, we have treated our patients in deep breathing (DIBH) using the “voluntary breath-hold” technique. We compared the Dmean and Dmax values for the most critical OAR (left lung, heart, left ventricle, LAD-left anterior descending artery) based on the two treatment methodologies. Subsequently, both groups were then further subdivided into whether the treatment was given by standard fractionation or hypofractionation and created 3-3 groups based on the size of the target area (PTV).
Results
In patients treated with normal fractionation in DIBH vs. without, the doses of the OARs were the following: lung Dmean: 9.3 Gy vs. 9.96 Gy (p=0.029), left ventricle Dmean: 3.52 Gy vs. 7.56 Gy (p=2.69E-27), heart Dmean: 2.78 vs. 5.31 (p=1.11E-24), LAD Dmean 12.17 vs. 25.91 Gy (p=4.63E-24) respectively. In the hypofractionated group with vs. without DIBH the values were lung Dmean: 7.43 Gy vs. 8.08 Gy (p=0.17), left ventricle Dmean: 3.48 Gy vs 6.4 Gy (p=2.64E-10), heart Dmean: 2.64 vs 4.62 (p=2.96E-08), LAD Dmean 11.46 vs 18.35 Gy (p=3.37E-06) respectively. In the standard fractionated group, the average doses for each structure decreased mostly in women with large breast sizes after DIBH treatment. Generally, as the breast size increases, the values of the left ventricle, heart, and LAD increase, whilst the values of the lungs decrease. Although, a significant difference could only be detected in a few categories.
Conclusions
DIBH RT of the left breast significantly reduces radiation exposure to crucial OAR than free-breathing radiation therapy. At the same time, the coverage of the target area does not change, and our results suggest that this benefit is most pronounced in patients with large breast sizes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
303P - Differential prognostic role of PDGFRA alterations in breast cancer subtypes
Presenter: Panagiotis Vlachostergios
Session: Poster session 02
304P - Generalizability of 313-SNP PRS for breast cancer risk in non-European ancestries
Presenter: Helen Shang
Session: Poster session 02
305P - Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Presenter: Sora Kang
Session: Poster session 02
307P - Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Presenter: Xixuan Zhu
Session: Poster session 02
308P - Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Presenter: Omar El Nahhas
Session: Poster session 02
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
311P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience
Presenter: Ranjit Kaur
Session: Poster session 02
312P - Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Presenter: Dong Woo Lee
Session: Poster session 02